LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.
What happened
FDA reviewed records LCC Ltd. submitted after FDA's March 3, 2023 request for records; there was no inspection. FDA found the firm did not test each shipment and lot of high-risk components such as glycerin and propylene glycol for identity, including limits for diethylene glycol (DEG) and ethylene glycol (EG) contamination, and that its quality unit did not adequately approve or reject components. FDA placed the firm on Import Alert 66-40 on May 3, 2023.
What FDA found
LCC Ltd. did not perform at least one identity test on each shipment of each lot of high-risk components, including glycerin and propylene glycol, to detect diethylene glycol (DEG) or ethylene glycol (EG).
21 CFR 211.84(d)(1)Its quality control unit did not effectively use its authority to approve or reject components.
21 CFR 211.22(a)
What FDA wants
Respond in writing within 30 working days and provide DEG and EG test results from retained high-risk component lots within 30 calendar days. Also provide a risk assessment for unexpired products, a component testing plan, quality-unit remediation, and consider a qualified manufacturing consultant.
Who should pay attention
- brands that buy finished OTC drugs from this contract manufacturer
- US importers and distributors of OTC drug products
- suppliers and buyers of glycerin or propylene glycol used in drugs
This is a summary. Read the original letter on fda.gov.